Abstract:The Bayesian optimal interval (BOIN) design is a novel phase I trial design for finding the maximum tolerated dose (MTD). It can be used to conduct both single-agent and drug-combination trials. The BOIN design is motivated by the top priority and concern of clinicians, which is to effectively treat patients and minimize the chance of exposing them to subtherapeutic or overly toxic doses. The most important advantage of the BOIN design is that it is easy to implement in practice and has superior operating characteristics. The BOIN design is algorithm-based and thus can be implemented in a way similar to the traditional “3+3” design. The performance of the BOIN design is comparable to that of the continual reassessment method (CRM, one of the best performing model-based phase I trial designs) in terms of selecting the MTD, but has a lower risk of assigning patients to subtherapeutic or overly toxic doses (i.e., better patient ethics). The idea behind the BOIN design is straightforward. The conduct of phase I trials can be viewed as a sequence of decision-making steps of dose assignment for patients who are sequentially enrolled into a trial. At each moment of decision making, based on the observed data, we take one of three actions: escalate, deescalate or retain the current dose. Under the standard assumption that efficacy monotonically increases with toxicity (for cytotoxic agents), an ideal trial design would escalate the dose when the current dose is below the MTD in order to avoid treating a patient at a subtherapeutic dose level; deescalate the dose when the current dose is above the MTD in order to avoid exposing a patient to an overly toxic dose; and retain the same dose level when the current dose is equal (or close) to the MTD. However, such an ideal design is not available in practice because we do not know whether the current dose is actually below, above or equal (or close) to the MTD, and need to

Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.

Statistical Tutorial for Using Bayesian Optimal Interval (BOIN) Design for Phase I Single-Agent and Drug-Combination Trials

Bayesian Optimal Interval Design for Phase I Oncology Clinical Trials

Bayesian Optimal Interval Designs for Phase I Clinical Trials

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

Gboin: a Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points

A Utility‐based Bayesian Optimal Interval (U‐BOIN) Phase I/II Design to Identify the Optimal Biological Dose for Targeted and Immune Therapies

BOIN: a Novel Bayesian Design Platform to Accelerate Early Phase Brain Tumor Clinical Trials

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Time-to-Event Model-Assisted Designs to Accelerate Phase I Clinical Trials

A90 a utility-based bayesian optimal interval (u-boin) phase i/ii design to identify the optimal biological dose for targeted and immune therapies

A Comparative Study of Bayesian Optimal Interval (BOIN) Design with Interval 3+3 (i3+3) Design for Phase I Oncology Dose-Finding Trials

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

PKBOIN-12: A Bayesian optimal interval Phase I/II design incorporating pharmacokinetics outcomes to find the optimal biological dose

Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN).

PKBOIN‐12: A Bayesian Optimal Interval Phase I/II Design Incorporating Pharmacokinetics Outcomes to Find the Optimal Biological Dose

Utpi: A Utility‐based Toxicity Probability Interval Design for Phase I/II Dose‐finding Trials

MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials